Downgrade to NEUTRAL with a lower TP of S$0.51 (previously S$0.65). With a more moderate pace of clinics expansion as well as lesser CHAS claims made by patients due to the government’s tightening measures, we lowered our FY18-FY19 revenue and PATMI estimates by 18-32% and 10-14% respectively. We reduce PER to 25x from 27x, which is line with peers’ average FY18e and FY19e PER (excluding hospitals).
The Negatives
– Muted clinics business growth. Revenue growth from both clinics and distribution at +0.40% YoY and -2.76% YoY respectively. Despite having more dental clinics in 3Q18 (89 clinics) as compared to 3Q17 (86 clinics), revenue was flat due to dampened patient demand under the CHAS and Pioneer Generation scheme as the government tightened claim limits this year. Q&M had been a beneficiary of this government initiative.
– The decrease of 2.8% YoY in distribution revenue was due to fewer purchases by the private sectors from both the Singapore and Malaysia distribution companies.
[Revenue for 9M18 is purely from Q&M, as Aidite and Aoxin were deconsolidated in Dec’16 and Apr’17 respectively; their profits are now recognized in share of profit from Associates, which fell 26.5% YoY due to lower share of profits.]
– Q&M is in a net debt position of S$63.1mn, S$52.6mn a year ago. Net debt has risen largely due to share buyback of S$4.7mn and dividends totalling S$10.5mn. Majority of debt is from a S$59.9mn three-year term loan to repay the MTN expiring in March 2018.
– Total dental clinics expanded by 3 YoY and 3 QoQ. As of November 2018, Q&M has signed agreements to open three new clinics in Singapore and four new clinics in Malaysia. As we approach the tail end of the year, it seems that Q&M’s aggressive expansion plan to add ten new dental clinics in Singapore and Malaysia each for 2018 will likely fall short.
The Positive
+Gross profit margins for respective businesses reverted to their pre-acquisition levels. Clinic margins at c.93% and Distribution margin at c.30%.
Outlook
We are cautiously optimistic about the expansion plans in Singapore and Malaysia. Post-deconsolidation of its major revenue drivers in China, the Group is stepping up its regional expansion in Singapore and Malaysia to plug the gap.
We do not discount the possibility that the Group will expand into Southern China via joint ventures and organic growth initiatives with its Chinese associate, Aoxin Q&M Dental Group (the Group currently owns 43%). Aoxin Q&M Dental has a strong presence in Northern China.
Other updates
Potential new business – Education
With the MOH intending to release a new regulation in 1-2 years to require dentists practising aesthetic procedures to obtain a Certificate of Competency, Q&M is positioning themselves to be accredited by CPE as a teaching college for the dentistry profession in the next few quarters.
Exploring the use of Artificial Intelligence
With existing AI in the medical field mainly used in ECG and EEG diagnosis for the brain and heart, Q&M is experimenting with the use of AI to improve efficiency in the overall dental process. The dental AI process would require X-rays and scans of the patient’s mouth cavity, which is then run through an algorithm to come up with a treatment plan for both the patient and the doctor.
Investment Action
Downgrade to NEUTRAL with a lower TP of S$0.51 (previously S$0.65). With a more moderated pace of clinics expansion as well as lesser CHAS claims made by patients due to the government’s tightening measures, we lower our FY18-FY19 revenue and PATMI estimates by 18-32% and 10-14% respectively. We reduce PER to 25x from 27x, which is line with peers’ average FY18e and FY19e PER (excluding hospitals).
Potential re-rating catalysts would be (i) successful earnings accretive acquisitions; and (ii) better-than-expected results from associates.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
Min Ying covers the Banking and Finance sectors. She has experience in external audit and corporate tax roles.
She graduated with a Bachelor of Accountancy with a major in Finance from SMU.